The trial will enrol 330 PD patients with confirmed GBA1 status and the primary outcome will be the combined score of parts I, II, and III of the Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). The gene discussed is GBA1; the disease is movement disorder.